The value of c-kit mutational analysis in a cytokeratin positive gastrointestinal stromal tumour

G Rossi, G Sartori, R Valli, F Bertolini, N Bigiani, L Schirosi, A Cavazza, G Luppi

The expression of cytokeratins in gastrointestinal stromal tumours (GISTs) is rare and may lead to diagnostic confusion when it occurs. This report describes a metastatic GIST that stained strongly for cytokeratins, CD117, and CD34 in a patient who was previously diagnosed with gastric epithelioid angiosarcoma. A review of both tumours showed the same histological and immunohistochemical profiles, and c-kit molecular analysis revealed an insertional mutation at codon 558 of exon 11 in both tumours. Thus, pathologists should be aware that GISTs can occasionally express cytokeratins, and that c-kit mutational investigations may have a key diagnostic role and may prevent diagnostic mistakes that could have important clinical implications.

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal neoplasms of the digestive tract. The identification of KIT (CD117) as a specific immunohistochemical marker, together with the discovery of gain of function mutations in the protooncogene c-kit in most GISTs represent crucial steps in the definition of this tumour as a biologically distinctive malignancy and, most importantly, in the development of an alternative therapeutic approach using targeted treatment with a specific KIT inhibitor, imatinib mesylate (formerly known as STI571, Gleevac).

“Gastrointestinal stromal tumours are the most common mesenchymal neoplasms of the digestive tract”

In routine practice, when faced with a soft tissue tumour of the gastrointestinal tract, surgical pathologists usually use a small immunohistochemical panel of antibodies to support the morphological picture, including CD117, CD34, smooth muscle actin, desmin, and S-100 protein. In fact, almost all GISTs are CD117 positive and about 60–70% are CD34 immunopositive, whereas the other markers are usually negative. In this context, immunostaining for cytokeratins may be helpful to rule out the possibility of a sarcomatoid carcinoma, because GISTs are usually negative for epithelial markers.

Here, we describe a gastric GIST initially diagnosed as epithelioid angiosarcoma which metastasised to the pelvis and strongly expressed cytokeratins and CD117. Molecular analysis revealed the presence of a c-kit mutation in exon 11 in both tumours, thus confirming the diagnosis of GIST. The exceptionally rare occurrence of cytokeratin immunostaining in GISTs is also discussed.

CASE REPORT

In July 2003, a 32 year old woman originating from Ghana was admitted to our hospital as a result of a lack of appetite and abdominal discomfort resulting from a painful mass in the right iliac fossa. Her medical history revealed that four years previously she had undergone total gastrectomy plus omentectomy at another hospital for a gastric malignancy diagnosed as epithelioid angiosarcoma, for which she received adjuvant chemotherapy (doxorubicin and ifosfamide). Based on her previous diagnosis, metastatic disease was clinically suspected. Abdominal ultrasonography and a computerised tomography scan confirmed the presence of a large (8 cm across) solid mass in the right iliac region and a partially cystic mass (6 cm) in the left one. Radiological investigations revealed no significant signs in the other abdominal organs or regional lymph nodes. A chest x-ray was unremarkable. Tumour markers (CA125 and carcinoembryonic antigen) and laboratory studies were negative. The patient then underwent complete surgical excision of the pelvic masses and right adnexectomy. The surgical specimen, routinely formalin fixed and paraffin wax embedded, grossly showed a grey/whitish cut surface with bloody areas. At histology, the tumour appeared as a proliferation of polygonal to round epithelioid cells, with abundant lightly eosinophilic cytoplasm and centrally located nucleus (fig 1A). Clear perinuclear vacuoles were seen. Mitotic activity was very high (18 mitoses/×50 high power field) and foci of punctate necrosis were found.

Immunohistochemistry revealed that the neoplastic elements were strongly positive for CD117 (polyclonal antibody, A4502; 1/200 dilution; no antigen retrieval; Dako, Glostrup, Denmark) (fig 1B), CD34 (monoclonal QB-END/10; 1/40 dilution; antigen retrieval, microwave; Novocastra, Newcastle upon Tyne, UK) bcl-2 (monoclonal; 1/10 dilution; antigen retrieval, microwave; Ventana, Tucson, Arizona, USA), AE1/AE3 (monoclonal; prediluted; antigen retrieval, protease; Ventana), MNF16 (monoclonal; 1/1500 dilution; antigen retrieval, microwave; Ventana), CAM5.2 (monoclonal; 1/50 dilution; no antigen retrieval; Becton Dickinson, San José, California, USA) (fig 1C), but did not stain for high molecular weight cytokeratins (monoclonal 34BE12; 1/500 dilution; antigen retrieval, microwave; Dako), CD31 (monoclonal JC/70A; prediluted; antigen retrieval, protease; Ventana), epithelial membrane antigen (monoclonal E29; 1/300 dilution; no antigen retrieval; Dako), desmin (monoclonal D33; 1/10 dilution; antigen retrieval, microwave; Dako), smooth muscle actin (monoclonal 1A4; 1/20 dilution; no antigen retrieval; Biogenex, San Ramon, California, USA), S-100 (polyclonal; 1/5 dilution; no antigen retrieval; NeoMarkers, Freemont, California, USA), chromogranin (monoclonal DAK-A3; 1/100 dilution; antigen retrieval, microwave; Dako), HMB-45 (monoclonal HMB-45; prediluted; antigen retrieval, microwave; Ventana), or h-caldesmon (monoclonal hCD; 1/100 dilution; antigen retrieval, microwave; Dako).

Abbreviations: GIST, gastrointestinal stromal tumour; PCR, polymerase chain reaction
Sequences from a representative paraffin wax embedded block were dewaxed by xylene and tumour DNA was extracted using a laser capture microdissection method (LaserScissor-PRO300; Olympus, Tokyo, Japan). Microdissected tumour cells were subjected to proteinase K treatment in extraction buffer (50mM Tris/HCl (pH 8.0), 1mM EDTA, 0.5% Tween 20) and then incubated overnight at 37˚C. Polymerase chain reaction (PCR) was performed in 10 μl reactions containing 1.0 μl DNA, 10mM Tris/HCl (pH 8.3), 40mM KCl, 1.0–1.5mM MgCl₂, 200mM each dNTP, 20pM of each primer, and 0.25 U Platinum Taq polymerase. The PCR reaction was carried out on a Uno II Thermoblock (Biometra, Gottingen, Germany). Initial denaturation at 94˚C for three minutes was followed by 41 cycles of denaturation at 95˚C for one minute, annealing at 53–58˚C for 40 seconds, and extension at 72˚C for 35 seconds, with a final extension step of five minutes at 72˚C. The amplified DNA was electrophoresed on a 1% low melt agarose gel for one hour. The amplification products were then excised from the gel and purified using Wizard PCR Preps-DNA purification system (Promega Corp, Madison, Wisconsin, USA), as indicated by the manufacturer. The PCR products were then sequenced in both directions with the BigDye Terminator (Applied Biosystems, Weiterstadt, Germany) sequencing kit, using the same primers as those used for PCR. PCR products were finally purified by Centri-Sep spin columns and subsequently analysed using the ABIPrism 310 sequence analyser (Applied Biosystems). The following oligonucleotide primers were used to amplify c-kit exons 9 and 11: exon 9 (forward, 5’-ATG CTC TGC TTC TGT ACT GCC-3’; reverse, 5’-CAG AGC CTA AAC ATC CCC TTA-3’; 238 bp; 58˚C annealing temperature), exon 11 (forward, 5’-CTA TTT TTC CCT TTC TCC CC-3’; reverse, 5’-TAC CCA AAA AGG TGA CAT GG-3’; 193 bp; 53˚C annealing temperature).

Molecular analysis revealed a c-kit mutation consisting of an insertion of the TCC nucleotides at codon 558 (fig 2). The histological review of the previously diagnosed gastric tumour showed a similar epithelioid malignancy with immunohistochemical features identical to those seen in the pelvic metastatic deposits. Most importantly, the original gastric tumour revealed the same insertion mutation found in the metastatic deposits. Thus, a diagnosis of metastatic GIST was rendered and the patient started treatment with Glivec® (400 mg/day). She is alive and well at 22 months follow up.

**DISCUSSION**

GISTs are well defined clinicopathological tumours and are the most frequent mesenchymal malignancies found in the digestive tract. They are characterised by the expression of the type III tyrosine kinase KIT, the product of the protooncogene c-kit, recognised by the antibody CD117. Most importantly, c-kit activating gain of function mutations occur in most GISTs, whereas a small subset of GISTs are KIT negative and lack c-kit mutations. These KIT negative tumours show activating mutations of the PDGFRA gene, encoding the type III tyrosine kinase PDGFR-α.

![Figure 1](A) The tumour appeared as an epithelioid cell proliferation consistent with gastrointestinal stromal tumour and was strongly immunopositive for (B) CD117 and (C) cytokeratin.

![Figure 2](Molecular analysis revealed the presence of an insertion mutation on codon 558 of the c-kit exon 11 (arrow).)
Case report

Take home messages

• We describe a metastatic gastrointestinal stromal tumour (GIST) that stained strongly for cytokeratins, CD117, and CD34 in a patient previously diagnosed with gastric epithelioid angiosarcoma.

• Both tumours showed the same histological and immunohistochemical profiles, and c-kit molecular analysis revealed the same mutation in both tumours.

• Thus, pathologists should be aware that GISTs can occasionally express cytokeratins and that c-kit mutational analysis may help in diagnosis and prevent mistakes that could have important clinical implications.

Most GISTs display a spindle, epithelioid, or mixed (spindle/epithelioid) cell morphology, but they may show a broad spectrum of histological growth patterns that make the differential diagnosis difficult, and may be confused with smooth muscle tumours, desmoid, neural tumours, neuroendocrine tumours, inflammatory myofibroblastic tumour and fibroid polyp, synovial sarcoma, sarcomatoid carcinoma, and angiosarcoma. For this reason, immunostaining is mandatory, not only to achieve the diagnosis, but also because of the clinical implications of a diagnosis of GIST. As suggested by Fletcher et al., the diagnosis of GIST should be based not only on morphological grounds, but also because of the small panel of antibodies should also be performed to rule out other mimicking tumours. Here, we report a rare case of metastatic GIST strongly expressing c-kit, in addition to CD34 and CD117, and originally thought to be a gastric epithelioid angiosarcoma.

Ng and colleagues14 recently reported a case of cytokeratin positive pleural metastatic GIST initially suspected to be lung carcinoma and found two other GISTs showing focal, dot-like immunoreactivity for CAM5.2 in a series of 41 GISTs. Of note, all these cytokeratin positive GISTs had a gastric origin. Although extremely rare, this has been described previously by Miettinen et al.,13 who found two keratin 18 positive tumours in a series of 57 anorectal GISTs. In both studies, no GIST showed immunostaining for other epithelial markers (such as AE1/AE3 and epithelial membrane antigen).

“Insertional mutation in codon 558 of c-kit exon 11 has been reported previously in gastrointestinal stromal tumours, and seems to be related to a good clinical response rate with STI571.”

Apart from GIST, CD117 expression has been reported in several other tumours, mainly as a result of the presence of different commercially available antibodies against KIT and the use of inappropriate technical protocols. Among tumours coexpressing CD34 and cytokeratins, CD117 immunoreactivity has been reported in angiosarcoma only. Even though angiosarcomas may primarily arise from the stomach, they lack c-kit mutations and generally carry a worse prognosis than that of GIST.

Mutational analysis of c-kit appears to be extremely helpful, if not mandatory, in confirming the diagnosis of GIST when this tumour shows an unusual presentation on clinical, morphological, and/or immunohistochemical grounds, as in our case. In addition, insertion mutation in codon 558 of c-kit exon 11 has been reported previously in GIST, and seems to be related to a good clinical response rate with STI571.15

Finally, pathologists should be aware that, although unusual, GISTs may express cytokeratins, and this should be kept in mind when dealing with small biopsies to prevent an erroneous diagnosis.

Authors’ affiliations
G Rossi, S Sartori, R Valli, N Bigiani, I Schirosi, Integrated Department of Diagnostic and Laboratory Services and Legal Medicine, Section of Pathologic Anatomy, University of Modena and Reggio Emilia, via del Pozzo 71, 41100 Modena, Italy
F Bertolini, G Luppi, Department of Oncology and Haematology, Section of Oncology, University of Modena and Reggio Emilia
A Cavazzo, Department of Pathology, S. Maria Nuova Hospital, Viale Risorgimento 80, 42100 Reggio Emilia, Italy

The patient gave her full permission for this case report to be published

Correspondence to: Dr G Rossi, Dipartimento Integrato di Servizi Diagnostici, di Laboratorio e di Medicina Legale, Sezione di Anatomia Patologica, Università di Modena e Reggio Emilia, via del Pozzo 71, 41100 Modena, Italy; rossi.giulio@unimo.it

Accepted for publication 17 January 2005

REFERENCES

The value of c-kit mutational analysis in a cytokeratin positive gastrointestinal stromal tumour

G Rossi, G Sartori, R Valli, F Bertolini, N Bigiani, L Schirosi, A Cavazza and G Luppi

*J Clin Pathol* 2005 58: 991-993
doi: 10.1136/jcp.2004.024364

Updated information and services can be found at:
http://jcp.bmj.com/content/58/9/991

**References**

This article cites 16 articles, 5 of which you can access for free at:
http://jcp.bmj.com/content/58/9/991#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Immunology (including allergy) (1664)
- Molecular genetics (355)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/